Hemophilia care in China: review of care for 417 hemophilia patients from 11 treatment centers in Shanxi Province

References

• Srivastava A, Brewer AK, Mauser-Bunschoten EP, et al. Guidelines for the management of hemophilia. Haemophilia 2013;19(1):e1-47
   PubMed Web of Science ®Google Scholar
• O’Mahony B, Black C. Expanding hemophilia care in developing countries. Semin Thromb Hemost 2005;31(5):561-8
   PubMed Web of Science ®Google Scholar
• Verbruggen B, Novakova I, Wessels H, et al. The Nijmegen modification of the Bethesda assay for factor VIII:C inhibitors: improved specificity and reliability. Thromb Haemost 1995;73(2):247-51
   PubMed Web of Science ®Google Scholar
• Verbruggen B, van Heerde WL, Laros-van Gorkom BA. Improvements in factor VIII inhibitor detection: From Bethesda to Nijmegen. Semin Thromb Hemost 2009;35(8):752-9
   PubMed Web of Science ®Google Scholar
• Keeney S, Mitchell M, Goodeve A. The molecular analysis of haemophilia A:a guideline from the UK haemophilia centre doctors’ organization haemophilia genetics laboratory network. Haemophilia 2005;11(4):387-97
   PubMedGoogle Scholar
• Pettersson H, Ahlberg Å, Nilsson IM. A radiologic classification of hemophilic arthropathy. Clin Orthop Relat Res 1980;149:153-9
   PubMed Web of Science ®Google Scholar
• Stonebraker JS, Bolton-Maggs PH, Soucie JM, et al. A study of variations in the reported haemophilia A prevalence around the world. Haemophilia 2010;16(1):20-32
   PubMed Web of Science ®Google Scholar
• Poon MC, Luke KH. Haemophilia care in China: achievements of a decade of World Federation of Hemophilia treatment centre twinning activities. Haemophilia 2008;14(5):879-88
   PubMed Web of Science ®Google Scholar
• Evatt B. World Federation of Hemophilia guide to developing a national patient registry. World Fed Hemophilia 2005;1:1-22
   Google Scholar
• Wu RH, Wu X, Zhang NN, et al. Evaluation clinical data and current condition of children hemophilic patients in China. Chin J Thromb Haemost 2008;14(3):116-20
   PubMedGoogle Scholar
• Novo Nordisk Haemophilia Foundation Report 2007/2008. Novo Nordisk Haemophilia Foundation; Zurich, Switzerland: 2008
   Google Scholar
• Zhang L, Li H, Zhao H, et al. Retrospective analysis of 1312 patients with haemophilia and related disorders in a single Chinese institute. Haemophilia 2003;9(6):696-702
   PubMed Web of Science ®Google Scholar
• Manco-Johnson MJ, Abshire TC, Shapiro AD, et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med 2007;357(6):535-44
   PubMed Web of Science ®Google Scholar
• Steen Carlsson K, Hojgard S, Glomstein A, et al. On-demand vs. prophylactic treatment for severe haemophilia in Norway and Sweden: differences in treatment characteristics and outcome. Haemophilia 2003;9(5):555-66
   PubMed Web of Science ®Google Scholar
• Srivastava A. Factor replacement therapy in haemophilia –are there models for developing countries? Haemophilia 2003;9(4):391-6
   PubMed Web of Science ®Google Scholar
• Globe DR, Curtis RG, Koerper MA. Utilization of care in haemophilia: a resource-based method for cost analysis from the Haemophilia Utilization Group Study (HUGS). Haemophilia 2004;10(Suppl 1):63-70
   PubMed Web of Science ®Google Scholar
• Li M. A survey of short-term prophylaxis in low-dose for children with hemophilia A. Master thesis. Southern Medical University, Guangzhou, Guangdong, China, 2009
   Google Scholar
• Evatt BL. Observations from Global Survey 2001: an emerging database for progress. Haemophilia 2002;8(2):153-6
   PubMed Web of Science ®Google Scholar
• Wang XF, Zhao YQ, Yang RC, et al. The prevalence of factor VIII inhibitors and genetic aspects of inhibitor development in Chinese patients with haemophilia A. Haemophilia 2010;16(4):632-9
   PubMed Web of Science ®Google Scholar
• Astermark J, Altisent C, Batorova A, et al. Non-genetic risk factors and the development of inhibitors in haemophilia: a comprehensive review and consensus report. Haemophilia 2010;16(5):747-66
   PubMed Web of Science ®Google Scholar
• Wight J, Paisley S. The epidemiology of inhibitors in haemophilia A: a systematic review. Haemophilia 2003;9(4):418-35
   PubMed Web of Science ®Google Scholar
• Xu XC, Wu JS, Sun ZM, et al. Retrospective study on 500 haemophilia patients. J Clin Hematol 2001;14(6):255-7
   Google Scholar
• Zhang LL, Yu ZQ, Zhang W, Ruan CG. Analysis of coagulation factor VIII inhibitor development related factors in hemophilia A patients. Chinese J Hematol 2010;31(3):168-71
   Google Scholar
• Guo Y, Jiang B. Factors analysis of factor VIII inhibitors in the patients with hemophilia A. Chinese J Intern Med 2005;44(10):773-4
   Google Scholar
• Lakich D, Kazazian HHJr, Antonarakis SE, et al. Inversions disrupting the factor VIII gene are a common cause of severe haemophilia A. Nat Genet 1993;5(3):236-41
   PubMed Web of Science ®Google Scholar
• Cumming AM; UK Haemophilia Centre Doctors’ Organization Haemophilia Genetics Laboratory Network. The factor VIII gene intron 1 inversion mutation: prevalence in severe hemophilia A patients in the UK. J Thromb Haemost 2004;2(1):205-6
   PubMed Web of Science ®Google Scholar
• Lee CA, Lillicrap D, Astermark J. Inhibitor development in hemophiliacs: the roles of genetic versus environmental factors. Semin Thromb Hemost 2006;32(Suppl 2):10-14
   PubMedGoogle Scholar
• Schroder J, El-Maarri O, Schwaab R, et al. Factor VIII intron-1 inversion: frequency and inhibitor prevalence. J Thromb Haemost 2006;4(5):1141-3
   PubMed Web of Science ®Google Scholar
• Available from: http://hadb.org.uk/
   Google Scholar
• Guo ZP, Yang LH, Qin XY, et al. Comprehensive analysis of phenotypes and genetics in 21 Chinese families with haemophilia B: characterization of five novel mutations. Haemophilia 2014;20(6):859-65
   PubMedGoogle Scholar